Abstract
Plain language summary
We conducted a systematic review and metaregression of pivotal Crohn’s disease trials to evaluate the rates of change in Crohn’s Disease Activity Index scores in patients receiving biologic treatments. The speed of clinical improvement was similar among biologic drug classes.